131 related articles for article (PubMed ID: 16531261)
1. Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Ducastelle S; Adès L; Gardin C; Dombret H; Prébet T; Deconinck E; Rio B; Thomas X; Debotton S; Guerci A; Gratecos N; Stamatoullas A; Fegueux N; Dreyfus F; Fenaux P; Wattel E
Haematologica; 2006 Mar; 91(3):373-6. PubMed ID: 16531261
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.
Laudi N; Arora M; Burns LJ; Miller JS; McGlave PB; Barker JN; Ramsay NK; Orchard PJ; Macmillan ML; Weisdorf DJ
Biol Blood Marrow Transplant; 2005 Feb; 11(2):129-35. PubMed ID: 15682074
[TBL] [Abstract][Full Text] [Related]
3. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
Kröger N; Brand R; van Biezen A; Cahn JY; Slavin S; Blaise D; Sierra J; Zander A; Niederwieser D; de Witte T;
Bone Marrow Transplant; 2006 Jan; 37(2):183-9. PubMed ID: 16299545
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities.
van der Straaten HM; van Biezen A; Brand R; Schattenberg AV; Egeler RM; Barge RM; Cornelissen JJ; Schouten HC; Ossenkoppele GJ; Verdonck LF;
Haematologica; 2005 Oct; 90(10):1339-45. PubMed ID: 16219570
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.
Wong R; Shahjahan M; Wang X; Thall PF; De Lima M; Khouri I; Gajewski J; Alamo J; Couriel D; Andersson BS; Donato M; Hosing C; Komanduri K; Anderlini P; Molldrem J; Ueno NT; Estey E; Ippoliti C; Champlin R; Giralt S
Biol Blood Marrow Transplant; 2005 Feb; 11(2):108-14. PubMed ID: 15682071
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients > or =60 years with acute myelogenous leukemia.
Lashkari A; Lowe T; Collisson E; Paquette R; Emmanouilides C; Territo M; Schiller G
Biol Blood Marrow Transplant; 2006 Apr; 12(4):466-71. PubMed ID: 16545730
[TBL] [Abstract][Full Text] [Related]
7. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
8. Autologous stem cell transplantation for elderly patients with acute myeloid leukaemia conditioned with continuous infusion idarubicin and busulphan.
Ferrara F; Palmieri S; Pedata M; Viola A; Izzo T; Criscuolo C; Mele G
Hematol Oncol; 2009 Mar; 27(1):40-5. PubMed ID: 19206083
[TBL] [Abstract][Full Text] [Related]
9. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Andresen S; Kuczkowski E; Bolwell B
J Clin Oncol; 2006 Aug; 24(22):3604-10. PubMed ID: 16877727
[TBL] [Abstract][Full Text] [Related]
10. Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission.
Fouillard L; Labopin M; Gratwohl A; Gluckman E; Frassoni F; Beelen DW; Willemze R; Montserrat E; Blaise D; Atienza AI; Sierra J; Santos M; Gorin NC; Rocha V;
Haematologica; 2008 Jun; 93(6):834-41. PubMed ID: 18469352
[TBL] [Abstract][Full Text] [Related]
11. Second allogeneic stem cell transplantation in myeloid malignancies.
Hartwig M; Ocheni S; Asenova S; Wiedemann B; Zabelina T; Ayuk F; Kabisch H; Erttmann R; Kröger N; Zander AR; Bacher U
Acta Haematol; 2009; 122(4):185-92. PubMed ID: 19887774
[TBL] [Abstract][Full Text] [Related]
12. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
[TBL] [Abstract][Full Text] [Related]
13. Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation.
Boehm A; Sperr WR; Leitner G; Worel N; Oehler L; Jaeger E; Mitterbauer M; Haas OA; Valent P; Kalhs P; Rabitsch W
Eur J Clin Invest; 2008 Dec; 38(12):945-52. PubMed ID: 19021720
[TBL] [Abstract][Full Text] [Related]
14. Autologous stem cell transplantation for acute myeloid leukemia patients in first complete remission: a 10-year follow-up study of 118 patients.
Isidori A; Bonifazi F; Visani G; Gherlinzoni F; Baccarani M; Lemoli RM
Haematologica; 2005 Jan; 90(1):139-41. PubMed ID: 15642686
[TBL] [Abstract][Full Text] [Related]
15. Autologous stem cell transplantation in acute myeloid leukemia. Factors influencing outcome. A 13 year single institution experience.
Martins C; Lacerda JF; Lourenço F; Carmo JA; Lacerda JM
Acta Med Port; 2005; 18(5):329-37. PubMed ID: 16611537
[TBL] [Abstract][Full Text] [Related]
16. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
[TBL] [Abstract][Full Text] [Related]
17. Autologous stem cell transplantation in myelodysplastic syndromes.
de Witte T; Suciu S; Brand R; Muus P; Kröger N
Semin Hematol; 2007 Oct; 44(4):274-7. PubMed ID: 17961727
[TBL] [Abstract][Full Text] [Related]
18. Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation.
Abdelhameed A; Pond GR; Mitsakakis N; Brandwein J; Chun K; Gupta V; Kamel-Reid S; Lipton JH; Minden MD; Schimmer A; Schuh A; Yee K; Messner HA
Cancer; 2008 Apr; 112(7):1513-21. PubMed ID: 18286528
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation.
Wadehra N; Farag S; Bolwell B; Elder P; Penza S; Kalaycio M; Avalos B; Pohlman B; Marcucci G; Sobecks R; Lin T; Andrèsen S; Copelan E
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1343-9. PubMed ID: 17162217
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic stem cell transplantation in patients with myelodysplastic syndrome: outcome analysis according to the International Prognostic Scoring System.
Rubio S; Martins C; Lacerda JF; Carmo JA; Lourenço F; Lacerda JM
Acta Med Port; 2006; 19(5):343-7. PubMed ID: 17376319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
